Overview of the 2022 WHO classification of pituitary adenomas/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives

X Wan, J Chen, J Wang, Y Liu, K Shu, T Lei - Current Medical Science, 2022 - Springer
The latest edition of the WHO classification of the central nervous system was published in
2021. This review summarizes the major revisions to the classification of anterior pituitary …

[HTML][HTML] Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use

P Iglesias - Journal of Clinical Medicine, 2023 - mdpi.com
Pituitary neuroendocrine tumors (PitNETs) are the most common pituitary tumors and the
second most common brain tumors. Although the vast majority (> 90%) are benign, a small …

[HTML][HTML] PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas

G Cossu, S La Rosa, JP Brouland, N Pitteloud, E Harel… - Cancers, 2023 - mdpi.com
Simple Summary The biological behavior of Pituitary Neuroendocrine Tumors (PitNET)
remains unclear. Many efforts have been performed in order to clarify this point. The …

[HTML][HTML] Aggressive pituitary tumors (PitNETs)

H Nishioka - Endocrine journal, 2023 - jstage.jst.go.jp
The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not
metastasize, and were therefore called adenomas. However, they would frequently invade …

[HTML][HTML] Pituitary carcinoma-case series and review of the literature

S Du Four, J Van Der Veken, J Duerinck… - Frontiers in …, 2022 - frontiersin.org
Although pituitary adenomas (PAs) account for 15% of intracranial tumors, pituitary
carcinomas (PCs) are a rare entity. Most commonly, PCs evolve from aggressive PAs …

Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype

A Taguchi, Y Kinoshita, VJ Amatya, S Onishi, Y Go… - Neurosurgical …, 2023 - Springer
Purpose To clarify the invasiveness to surrounding structures and recurrence rate of each
subtype of nonfunctioning pituitary neuroendocrine tumor (Pit-NETs) according to the WHO …

Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments

B Chevalier, A Jannin, S Espiard, E Merlen, A Beron… - La Presse Médicale, 2022 - Elsevier
In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the
cornerstone. However, there are some limitations and MRI can be non-conclusive. The …

[HTML][HTML] The clinical and pathological characteristics of refractory pituitary adenomas: a single center experience

X Liu, C Dai, X Bao, K Deng, Y Yao, M Feng… - Frontiers in …, 2022 - frontiersin.org
Background Most of pituitary adenomas (PAs) are slow-growing benign tumors which can
be cured or controlled by conventional therapies, including surgery, medical treatment or …

[HTML][HTML] Endoscopic endonasal pituitary surgery: How we do it. Consensus statement on behalf of the EANS skull base section

I Bove, D Solari, M Bruneau, M Berhouma… - Brain and Spine, 2023 - Elsevier
Introduction and research question The use of an endoscope in skull base surgery provides
a panoramic close-up view over the intracranial structures from multiple angles with …

SPECIALTY SECTION This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology

S Du Four, J Van Der Veken, J Duerinck… - … in Pituitary Disorders, 2024 - books.google.com
Pituitary adenomas are a commonly encountered pathology, with an overall estimated
incidence of 16.7%(1). Most often, pituitary adenomas (PAs) are slow growing tumors that do …